Von Willebrand Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major von Willebrand disease markets reached a value of US$ 537.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 918.3 Million by 2034, exhibiting a growth rate (CAGR) of 4.98% during 2024-2034.
The von Willebrand disease market has been comprehensively analyzed in IMARC's new report titled "Von Willebrand Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Von Willebrand disease refers to an inherited bleeding disorder characterized by a deficiency or dysfunction of von Willebrand factor (vWF), a protein involved in blood clotting. The indications of this ailment can vary widely depending on the severity of the condition. Some patients with mild forms may have few or no symptoms, while others may experience frequent nosebleeds, easy bruising, prolonged bleeding after injuries, blood in the urine and stool, heavy menstrual periods in females, etc. In rare cases, this illness also manifests as spontaneous bleeding into joints or internal organs. The diagnosis of von Willebrand disease involves a combination of clinical evaluation, medical history assessment, and laboratory tests to measure the levels and activity of vWF in the blood. A healthcare provider will further perform a physical examination to look for signs of bleeding or clotting abnormalities, such as bruises or tiny red spots on the skin. Additionally, several other diagnostic workups, like factor VIII assay, ristocetin cofactor assay, platelet function tests, etc., are utilized to confirm a diagnosis among patients.
The increasing cases of inherited genetic mutations that affect the production, structure, or function of vWF are primarily driving the von Willebrand disease market. In addition to this, the inflating utilization of certain blood-thinning drugs, such as aspirin, which can interfere with the normal clotting process and enhance the risk of bleeding tendencies among individuals, is also creating a positive outlook for the market. Moreover, the widespread adoption of desmopressin therapy, since it stimulates the release of vWF from the endothelial cells, thereby increasing its levels in the bloodstream and providing symptom relief in patients, is further bolstering the market growth. Apart from this, the escalating application of antifibrinolytic agents, including tranexamic acid and epsilon-aminocaproic acid, to prevent the breakdown of blood clots and reduce bleeding incidences is acting as another significant growth-inducing factor. Additionally, the emerging popularity of cryoprecipitate therapy for the treatment of the ailment on account of its several associated benefits, such as the quicker onset of action, improved availability, elevated compatibility, etc., is expected to drive the von Willebrand disease market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the von Willebrand disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for von Willebrand disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the von Willebrand disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the von Willebrand disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the von Willebrand disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current von Willebrand disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the von Willebrand disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the von Willebrand disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the von Willebrand disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of von Willebrand disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of von Willebrand disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of von Willebrand disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with von Willebrand disease across the seven major markets?
What is the size of the von Willebrand disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of von Willebrand disease?
What will be the growth rate of patients across the seven major markets?
Von Willebrand Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for von Willebrand disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the von Willebrand disease market?
What are the key regulatory events related to the von Willebrand disease market?
What is the structure of clinical trial landscape by status related to the von Willebrand disease market?
What is the structure of clinical trial landscape by phase related to the von Willebrand disease market?
What is the structure of clinical trial landscape by route of administration related to the von Willebrand disease market?
The von Willebrand disease market has been comprehensively analyzed in IMARC's new report titled "Von Willebrand Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Von Willebrand disease refers to an inherited bleeding disorder characterized by a deficiency or dysfunction of von Willebrand factor (vWF), a protein involved in blood clotting. The indications of this ailment can vary widely depending on the severity of the condition. Some patients with mild forms may have few or no symptoms, while others may experience frequent nosebleeds, easy bruising, prolonged bleeding after injuries, blood in the urine and stool, heavy menstrual periods in females, etc. In rare cases, this illness also manifests as spontaneous bleeding into joints or internal organs. The diagnosis of von Willebrand disease involves a combination of clinical evaluation, medical history assessment, and laboratory tests to measure the levels and activity of vWF in the blood. A healthcare provider will further perform a physical examination to look for signs of bleeding or clotting abnormalities, such as bruises or tiny red spots on the skin. Additionally, several other diagnostic workups, like factor VIII assay, ristocetin cofactor assay, platelet function tests, etc., are utilized to confirm a diagnosis among patients.
The increasing cases of inherited genetic mutations that affect the production, structure, or function of vWF are primarily driving the von Willebrand disease market. In addition to this, the inflating utilization of certain blood-thinning drugs, such as aspirin, which can interfere with the normal clotting process and enhance the risk of bleeding tendencies among individuals, is also creating a positive outlook for the market. Moreover, the widespread adoption of desmopressin therapy, since it stimulates the release of vWF from the endothelial cells, thereby increasing its levels in the bloodstream and providing symptom relief in patients, is further bolstering the market growth. Apart from this, the escalating application of antifibrinolytic agents, including tranexamic acid and epsilon-aminocaproic acid, to prevent the breakdown of blood clots and reduce bleeding incidences is acting as another significant growth-inducing factor. Additionally, the emerging popularity of cryoprecipitate therapy for the treatment of the ailment on account of its several associated benefits, such as the quicker onset of action, improved availability, elevated compatibility, etc., is expected to drive the von Willebrand disease market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the von Willebrand disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for von Willebrand disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the von Willebrand disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the von Willebrand disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the von Willebrand disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current von Willebrand disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the von Willebrand disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the von Willebrand disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the von Willebrand disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of von Willebrand disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of von Willebrand disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of von Willebrand disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with von Willebrand disease across the seven major markets?
What is the size of the von Willebrand disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of von Willebrand disease?
What will be the growth rate of patients across the seven major markets?
Von Willebrand Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for von Willebrand disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the von Willebrand disease market?
What are the key regulatory events related to the von Willebrand disease market?
What is the structure of clinical trial landscape by status related to the von Willebrand disease market?
What is the structure of clinical trial landscape by phase related to the von Willebrand disease market?
What is the structure of clinical trial landscape by route of administration related to the von Willebrand disease market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 VON WILLEBRAND DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 VON WILLEBRAND DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 VON WILLEBRAND DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 VON WILLEBRAND DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 VON WILLEBRAND DISEASE - UNMET NEEDS
10 VON WILLEBRAND DISEASE - KEY ENDPOINTS OF TREATMENT
11 VON WILLEBRAND DISEASE - MARKETED PRODUCTS
11.1 List of Von Willebrand Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Wilate (Factor VIII/von Willebrand factor) - Octapharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Veyvondi (Vonicog alfa) - Takeda
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Alphanate (Factor VIII/von Willebrand factor) - Grifols
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Humate-P (Antihemophilic Factor/von Willebrand Factor Complex, Human) - CSL Behring
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 VON WILLEBRAND DISEASE - PIPELINE DRUGS
12.1 List of Von Willebrand Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Efanesoctocog alfa - Bioverativ/Sanofi
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 BT 200 - Guardian therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. VON WILLEBRAND DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. VON WILLEBRAND DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 VON WILLEBRAND DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Von Willebrand Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Von Willebrand Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Von Willebrand Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Von Willebrand Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Von Willebrand Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Von Willebrand Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Von Willebrand Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Von Willebrand Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Von Willebrand Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Von Willebrand Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Von Willebrand Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Von Willebrand Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Von Willebrand Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Von Willebrand Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Von Willebrand Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Von Willebrand Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Von Willebrand Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Von Willebrand Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Von Willebrand Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Von Willebrand Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Von Willebrand Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Von Willebrand Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Von Willebrand Disease - Access and Reimbursement Overview
16 VON WILLEBRAND DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 VON WILLEBRAND DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 VON WILLEBRAND DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 VON WILLEBRAND DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 VON WILLEBRAND DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 VON WILLEBRAND DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 VON WILLEBRAND DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 VON WILLEBRAND DISEASE - UNMET NEEDS
10 VON WILLEBRAND DISEASE - KEY ENDPOINTS OF TREATMENT
11 VON WILLEBRAND DISEASE - MARKETED PRODUCTS
11.1 List of Von Willebrand Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Wilate (Factor VIII/von Willebrand factor) - Octapharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Veyvondi (Vonicog alfa) - Takeda
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Alphanate (Factor VIII/von Willebrand factor) - Grifols
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Humate-P (Antihemophilic Factor/von Willebrand Factor Complex, Human) - CSL Behring
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 VON WILLEBRAND DISEASE - PIPELINE DRUGS
12.1 List of Von Willebrand Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Efanesoctocog alfa - Bioverativ/Sanofi
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 BT 200 - Guardian therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. VON WILLEBRAND DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. VON WILLEBRAND DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 VON WILLEBRAND DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Von Willebrand Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Von Willebrand Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Von Willebrand Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Von Willebrand Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Von Willebrand Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Von Willebrand Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Von Willebrand Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Von Willebrand Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Von Willebrand Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Von Willebrand Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Von Willebrand Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Von Willebrand Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Von Willebrand Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Von Willebrand Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Von Willebrand Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Von Willebrand Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Von Willebrand Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Von Willebrand Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Von Willebrand Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Von Willebrand Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Von Willebrand Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Von Willebrand Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Von Willebrand Disease - Access and Reimbursement Overview
16 VON WILLEBRAND DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 VON WILLEBRAND DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 VON WILLEBRAND DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
